Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Life Science Investing
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting Life Science Investing
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Life Science Investing
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors Life Science Investing
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 Life Science Investing
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results Life Science Investing
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Life Science Investing
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 Life Science Investing
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 Life Science Investing
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Life Science Investing
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Life Science Investing
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update Life Science Investing
